Anixa Biosciences Inc (NASDAQ:ANIX) Short Interest Update

Anixa Biosciences Inc (NASDAQ:ANIX) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 1,002,532 shares, a growth of 26.0% from the December 15th total of 795,400 shares. Based on an average trading volume of 292,147 shares, the short-interest ratio is currently 3.4 days. Approximately 4.1% of the shares of the stock are sold short. Approximately 4.1% of the shares of the stock are sold short. Based on an average trading volume of 292,147 shares, the short-interest ratio is currently 3.4 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ANIX shares. Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a report on Friday, December 12th. Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Anixa Biosciences in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $9.00.

Anixa Biosciences Price Performance

Shares of NASDAQ ANIX opened at $3.19 on Friday. Anixa Biosciences has a 12-month low of $2.33 and a 12-month high of $5.46. The company has a market capitalization of $106.48 million, a PE ratio of -9.11 and a beta of 0.49. The firm’s 50-day moving average is $3.88 and its two-hundred day moving average is $3.60.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Monday, January 12th. The company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). On average, analysts forecast that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ANIX. Susquehanna International Group LLP boosted its holdings in Anixa Biosciences by 378.4% in the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock valued at $265,000 after acquiring an additional 63,584 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Anixa Biosciences by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock valued at $4,694,000 after purchasing an additional 29,436 shares in the last quarter. Citadel Advisors LLC grew its holdings in shares of Anixa Biosciences by 31.6% during the 3rd quarter. Citadel Advisors LLC now owns 96,010 shares of the company’s stock worth $317,000 after purchasing an additional 23,072 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in shares of Anixa Biosciences during the 3rd quarter worth about $51,000. Finally, World Investment Advisors acquired a new stake in Anixa Biosciences during the 3rd quarter worth approximately $48,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.